ArticlePLoS neglected tropical diseases2025
Precise staging of severe fever with thrombocytopenia syndrome: Integrating the extent of organ damage for prognostic and therapeutic applications.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Aspartate aminotransferase-to-lymphocyte ratio predicts in-hospital mortality in patients with severe fever with thrombocytopenia syndrome: a multicenter retrospective cohort study.BMC infectious diseases · 2026Observational
- Standardized LDH-to-lymphocyte ratio improves early mortality prediction in severe fever with thrombocytopenia syndrome: A 15-day competing-risk bedside model.PLoS neglected tropical diseases · 2026Article
- Immunopathogenesis of Severe Fever with Thrombocytopenia Syndrome: Core Driving Role of Cytokine Storm.Current issues in molecular biology · 2026Review
- NLPR as a predictor of poor prognosis in patients with severe fever with thrombocytopenia syndrome: a prospective longitudinal study.Frontiers in cellular and infection microbiology · 2026Article
- A novel scoring system for precise severity quantification in severe fever with thrombocytopenia syndrome: development and application based on dynamic clinical data.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesThis study aimed to develop an accurate staging system for SFTS (Severe Fever with Thrombocytopenia Syndrome) based on the dynamic assessment of organ damage. This staging is intended to improve prognostication and guide treatment strategies.
methodsClinical data and laboratory parameters were analyzed from 77 fatal and 398 non-fatal cases of SFTS. Risk factors for mortality were identified using univariate Cox regression analysis. Dynamic changes in laboratory parameters and multi-organ dysfunction were systematically observed.
resultsBy dynamically analyzing clinical symptoms and laboratory parameters over the disease course, combined with assessing the number and severity of multi-organ dysfunction, SFTS progression was categorized into five distinct stages: initial (1-4 days), progressive (5-7 days), MOD (Multiple Organ Dysfunction) (8-10 days), remission (11-14 days), and convalescence (15-20 days). The critical phase, lasting approximately two weeks, accounted for 85.71% of patients succumbed within this two-week period, with 46.75% experiencing mortality during the MOD stage. Moreover, the study findings highlighted the effectiveness of intravenous immunoglobulin, including both its overall and early administration, in improving outcomes for patients with SFTS-associated myocarditis.
conclusionsThe progression of SFTS can be distinctly categorized into five distinct stages. Day 7 represents a critical juncture in disease progression, whereas Day 11 signifies a pivotal moment for clinical recovery. The progression stage is optimal for intervening to prevent further disease advancement. Treatment strategies should be adapted to the evolving patterns and severity of organ dysfunction. Myocarditis remains a significant challenge throughout SFTS progression, and early IVIG administration has been demonstrated to reduce mortality in patients with myocarditis complications significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.